- 29,000 volunteers
- participants were age 18 and older
- randomized, double-blind placebo experiment

Santa Clara University

- The Anhui Zhifei Longcom vaccine is a recombinant subunit vaccine
- June 19, 2020: approved for phase one clinical trials
- October 22, 2020: complete phase two clinical trials
- Entered Phase 3 clinical trials on November 20, 2020

Anhui Zhifei Longcom and the Chinese Academy of Medical Sciences Vaccine

Anhui Zhifei Longcom and Chinese Academy of Medical Science Vaccine
http://en.nhc.gov.cn/2020-11/20/c_82209.htm

National Health Commission of the People' Republic of China: A vaccine to undergo 3rd phase of trials

Anhui Zhifei Longcom and Chinese Academy of Medical Science Vaccine
https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3

South China Morning Post: Coronavirus: fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials 

Overview:
- Institute of Microbiology under the Chinese Academy of Sciences with Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. as co-developer
- June 19, 2020: approved for phase one
- October 22, 2020: ended phase two 
- November 20, 2020: approved for phase three
- Trial started in Xiangtan, Huan Province
- Trials will continue in Uzbekistan, with Indonesia, Pakistan, and Ecuador


Vaccine:
- Adjuvanted recombinant protein subunit (RBD-Dimer) vaccine
- Uses pieces of the SARS-COV2 protein components to trigger a protective immune response
- Induces humoral and a cell-mediated immune response


Overview of Anhui Zhifei Longcom and the Chinese Academy of Medical Sciences Vaccine

- 97% of trial participants developed high levels of neutralizing antibodies which is an indicator of immunity to the SARS-COV2 virus
- Antibody levels in the participants were two times the amount compared to a sample of 89 people who had COVID-19 and recovered from it.

Results of Anhui Zhifei Longcom and the Chinese Academy of Medical Sciences Vaccine

As of November 20, 2020:
- phase 2 results have not been published even though it had concluded at the end of October
- Potentially more expensive
- Adjuvants may be required later on to reignite the immune response
- Because the vaccine uses a protein, it is not necessary to have a high biosafety level in the production facility
- More people could have access to the vaccine

As of January 26, 2021
- he government is continuing with this vaccine.
- Plan to run last stage human trials through a private research organization in Bangladesh.
- Requires time to complete the procedures.

Conclusion of Anhui Zhifei Longcom and the Chinese Academy of Medical Sciences Vaccine

- Since it is not a live pathogen, there is little risk to the vaccine
- Determined to be generally safe and effective based on data that was gathered from phase one and phase two


Learn Before

Related